Continuing the Story: AstraZeneca and Mindpeak GmbH present new real-world results on AI-assisted HER2 scoring at ASCO 2025Following our oral presentation last Friday on the AI-assisted training for HER2 IHC interpretation, we are proud to share insights on the Monday’s poster session that took place at this year American Society of Clinical Oncology (ASCO) Annual Meeting.This time, it’s about real-world diagnostics. In collaboration with six academic centers across the globe, we evaluated whether AI can truly enhance accuracy and consistency in daily pathology practice.And the answer is clear:AI support boosted diagnostic agreement among pathologists to 86.4% for HER2-low and by 15% to 80.6% for HER2-ultralow - a major leap in consensus for some of the most challenging scoring decisions.Misclassification of HER2-null cases dropped by 64.5%, meaning more patients who may benefit from novel therapies like Enhertu can now be correctly identified.Accuracy rose across the board, especially in the critical 0 vs. 1+ distinction - an area long known for variability and clinical impact.Together, the oral and poster presentations offer a comprehensive view of how AI can support reproducible, high-quality HER2 assessment at scale - from training to clinical practice.As the clinical importance of HER2-low and ultralow scoring continues to grow, our findings provide strong evidence that AI can play a pivotal role in expanding access to targeted therapies like Enhertu - by enabling greater diagnostic precision.
Continuing the Story: AstraZeneca and Mindpeak GmbH present new real-world results on AI-assisted HER2 scoring at ASCO 2025
Related reading
Mindpeak in Oncology Times
We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.
As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.
At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.
AI-Enabled Pathology: De-risking Oncology Drug Development
We are delighted to share that Aurélie Fugon, VP Predictive AI Solutions at Mindpeak, is featured in Life Science Daily News.
In her article, Aurélie outlines how AI-supported biomarker-driven strategies can reduce variability in pathology, improve the consistency of patient selection and help de-risk late-stage trials.
All key enablers of more reliable, data-rich clinical decision-making. With Aurélie’s leadership, we’re strengthening collaborations with pharma, biotech and clinical partners to help bring reproducible, scalable biomarker assessment into real-world research settings, shaping the future of predictive AI in precision oncology.
Read the full article here: https://lifesciencedaily.news/ai-enabled-pathology-de-risking-oncology-drug-development/
United by Unique: Advancing Personalised Cancer Care on World Cancer Day
Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.
This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.
At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.
Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.
On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.
Ready to advance your diagnostics
Connect with our team to explore how precision pathology works in your setting